Si è verificato un errore durante il caricamento della pagina.
Il nostro team è stato avvisato ma contattaci tramite il Widget assistenza email se il problema persiste.
| Metrics | Range | Conclusion |
|---|---|---|
| Selected LTM EBIT Multiple | 8,0x - 8,8x | 8,4x |
| Selected Fwd EBIT Multiple | 5,7x - 6,3x | 6,0x |
| Fair Value | ₩14.572 - ₩16.507 | ₩15.539 |
| Upside | 21,6% - 37,8% | 29,7% |
| Benchmarks | Ticker | Full Ticker |
| BCWORLD PHARM. Co., Ltd. | A200780 | KOSDAQ:A200780 |
| Kyung Dong Pharmaceutical Co., Ltd. | A011040 | KOSDAQ:A011040 |
| Ahn-Gook Pharmaceutical Co., Ltd. | A001540 | KOSDAQ:A001540 |
| Dongwha Pharm.Co.,Ltd | A000020 | KOSE:A000020 |
| Whan In Pharm Co.,Ltd. | A016580 | KOSE:A016580 |
| JW Lifescience Corporation | A234080 | KOSE:A234080 |
| - | - | - |
| Select LTM EBIT Multiple | |||||||
| Benchmark Companies | |||||||
| A200780 | A011040 | A001540 | A000020 | A016580 | A234080 | ||
| KOSDAQ:A200780 | KOSDAQ:A011040 | KOSDAQ:A001540 | KOSE:A000020 | KOSE:A016580 | KOSE:A234080 | ||
| Historical EBIT Growth | |||||||
| 5Y CAGR | NM- | -36.1% | 22.5% | 7.1% | -3.9% | 3.8% | |
| 3Y CAGR | NM- | -45.0% | NM- | -15.8% | -11.8% | 8.1% | |
| Latest Twelve Months | -69.8% | 110.5% | 31.9% | -28.2% | -40.7% | 16.2% | |
| Historical EBIT Profit Margin | |||||||
| 5 Year Average Margin | -0.2% | 3.1% | 1.8% | 6.9% | 14.4% | 16.7% | |
| Prior Fiscal Year | 8.5% | -15.3% | 2.2% | 5.2% | 13.1% | 14.9% | |
| Latest Fiscal Year | 2.0% | 1.4% | 2.5% | 2.9% | 8.3% | 16.1% | |
| Latest Twelve Months | 1.7% | 1.4% | 2.5% | 2.9% | 7.1% | 16.1% | |
| Current Trading Multiples | |||||||
| EV / LTM Revenue | 1.59x | 0.51x | 0.38x | 0.41x | 0.33x | 1.10x | |
| EV / LTM EBITDA | 13.0x | 12.2x | 7.2x | 5.8x | 3.1x | 4.8x | |
| EV / LTM EBIT | 79.4x | 37.4x | 15.4x | 14.4x | 4.7x | 6.8x | |
| Low | Mid | High | |||||
| Benchmark EV / LTM EBIT | 4.7x | 15.4x | 79.4x | ||||
| Historical EV / LTM EBIT | 6.8x | 8.1x | 10.0x | ||||
| Selected EV / LTM EBIT | 8.0x | 8.4x | 8.8x | ||||
| (x) LTM EBIT | 35,858 | 35,858 | 35,858 | ||||
| (=) Implied Enterprise Value | 285,357 | 300,375 | 315,394 | ||||
| (-) Non-shareholder Claims * | (59,057) | (59,057) | (59,057) | ||||
| (=) Equity Value | 226,299 | 241,318 | 256,337 | ||||
| (/) Shares Outstanding | 15.5 | 15.5 | 15.5 | ||||
| Implied Value Range | 14,614.51 | 15,584.43 | 16,554.35 | ||||
| FX Rate: KRW/KRW | 1.0 | 1.0 | 1.0 | Market Price | |||
| Implied Value Range (Trading Cur) | 14,614.51 | 15,584.43 | 16,554.35 | 11,980.00 | |||
| Upside / (Downside) | 22.0% | 30.1% | 38.2% | ||||
| Equity Waterfall | |||||||
| Benchmark Companies | |||||||
| (in millions) | A200780 | A011040 | A001540 | A000020 | A016580 | A234080 | |
| Enterprise Value | 119,018 | 98,249 | 103,114 | 192,463 | 86,317 | 244,562 | |
| (+) Cash & Short Term Investments | 7,143 | 30,913 | 29,738 | 43,497 | 54,601 | 9,622 | |
| (+) Investments & Other | 2,999 | 69,556 | 28,043 | 65,942 | 31,625 | 559 | |
| (-) Debt | (86,917) | (38,677) | (77,724) | (96,989) | (788) | (69,238) | |
| (-) Other Liabilities | 479 | (276) | 932 | (28,304) | 0 | 0 | |
| (-) Preferred Stock | 0 | 0 | 0 | (1,154) | 0 | 0 | |
| (-) Other | 0 | 0 | 0 | 0 | 0 | 0 | |
| Value of Common Equity | 42,721 | 159,765 | 84,104 | 175,454 | 171,755 | 185,505 | |
| (/) Shares Outstanding | 9.2 | 26.9 | 11.4 | 27.7 | 15.3 | 15.5 | |
| Implied Stock Price | 4,625.00 | 5,930.00 | 7,400.00 | 6,330.00 | 11,250.00 | 11,980.00 | |
| FX Conversion Rate to Trading Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |
| Implied Stock Price (Trading Cur) | 4,625.00 | 5,930.00 | 7,400.00 | 6,330.00 | 11,250.00 | 11,980.00 | |
| Trading Currency | KRW | KRW | KRW | KRW | KRW | KRW | |
| FX Rate to Reporting Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |